Infed Injection
NDC Package 0404-9879-02
Package Information
Infed (iron dextran) injection is a medication used to treat "iron-poor" blood (anemia) in people who cannot take iron by mouth because of side effects or because their anemia has not been successfully treated by it. This formulation utilizes a injection delivery system. Marketed by Henry Schein, Inc., this product is identified by NDC 0404-9879 and is authorized under FDA application NDA017441.
Identification & Billing
- RxCUI: 206216 - INFeD 100 MG in 2 ML Injection
- RxCUI: 206216 - 2 ML iron-dextran complex 50 MG/ML Injection [InFed]
- RxCUI: 206216 - 2 ML InFed 50 MG/ML Injection
- RxCUI: 206216 - INFeD 100 MG per 2 ML Injection
- RxCUI: 311144 - iron dextran 100 MG in 2 ML Injection
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 0404 - Henry Schein, Inc.
- 0404-9879 - Infed
- 0404-9879-02 - 1 VIAL, SINGLE-DOSE in 1 BAG / 2 mL in 1 VIAL, SINGLE-DOSE
- 0404-9879 - Infed
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0404-9879-02 identifies a specific commercial package of 1 vial, single-dose in 1 bag / 2 ml in 1 vial, single-dose of Infed, a human prescription drug labeled by Henry Schein, Inc.. This injection is formulated for intramuscular; intravenous use and contains iron dextran as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Henry Schein, Inc. on January 11, 2022. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat "iron-poor" blood (anemia) in people who cannot take iron by mouth because of side effects or because their anemia has not been successfully treated by it. Low iron levels can occur when the body can't get enough iron from food (poor nutrition, poor absorption) or when there is a large or long-term blood loss (for example, due to hemophilia, stomach bleeding). It is also used by people who have anemia due to long-term kidney disease. Iron is an important part of your red blood cells and is needed to carry oxygen in the body.
How is this Henry Schein, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00404987902. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
